TNF Pharmaceuticals (TNFA) announced that it received written notice from Nasdaq on September 16, confirming that the company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550. To regain compliance with the listing rule, the company’s shares maintained the minimum bid price of $1.00 for 10 consecutive business days.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNFA:
- TNF Pharmaceuticals Secures $7M in Private Placement
- TNF Pharmaceuticals Enters Licensing Agreement with LightSolver
- PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M
- TNF Pharmaceuticals gets rights to LightSolver tech for crypto applications
- TNF Pharmaceuticals announces $7M private placement